Since 2010, guidelines recommend the use of the CHA2DS2-VASc score to estimate stroke risk in non-valvular atrial fibrillation (AF) patients [1]. The CHA2DS2-VASc is a simple, clinical risk factor-based approach to thromboprophylaxis, which has been validated in different cohorts and is widely used [2]. It has shown to help identify individuals with truly low thromboembolic risk (i.e. CHA2DS2-VASc score of 0 for men or 1 for women), who require no anticoagulation, thus simplifying anticoagulation decision-making [3].
